BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $331,911,771 | -9.9% | 4,876,036 | +8.0% | 1.36% | -0.8% |
| Q2 2023 | $368,484,187 | -12.0% | 4,514,078 | -20.0% | 1.37% | -7.9% |
| Q1 2023 | $418,498,148 | -29.4% | 5,640,897 | -21.1% | 1.49% | -33.2% |
| Q4 2022 | $592,919,127 | +40.9% | 7,153,947 | +382.9% | 2.23% | +52.0% |
| Q3 2022 | $420,706,000 | -8.2% | 1,481,360 | +12.1% | 1.47% | 0.0% |
| Q2 2022 | $458,061,000 | +51.4% | 1,321,431 | +89.2% | 1.47% | +49.7% |
| Q1 2022 | $302,472,000 | -99.6% | 698,486 | +274.9% | 0.98% | +278.4% |
| Q1 2021 | $71,153,941,000 | +4.9% | 186,301 | -12.8% | 0.26% | -6.8% |
| Q4 2020 | $67,809,945,000 | +1822.5% | 213,541 | +1498.7% | 0.28% | +1290.0% |
| Q2 2020 | $3,527,183,000 | -94.4% | 13,357 | -96.0% | 0.02% | -95.4% |
| Q1 2020 | $62,987,024,000 | +141.6% | 332,175 | +84.4% | 0.44% | +120.8% |
| Q4 2018 | $26,067,401,000 | -34.6% | 180,123 | -33.1% | 0.20% | -38.4% |
| Q2 2018 | $39,844,267,000 | -59.9% | 269,309 | -59.1% | 0.32% | -60.7% |
| Q1 2018 | $99,366,044,000 | -42.8% | 657,879 | -50.9% | 0.81% | -41.1% |
| Q4 2017 | $173,565,908,000 | -16.0% | 1,339,760 | -21.6% | 1.38% | -11.9% |
| Q3 2017 | $206,711,503,000 | -12.8% | 1,709,914 | -15.3% | 1.57% | -7.2% |
| Q2 2017 | $237,127,103,000 | -4.1% | 2,018,103 | -17.0% | 1.69% | -8.3% |
| Q1 2017 | $247,230,690,000 | +3.1% | 2,432,176 | +4.3% | 1.84% | -6.2% |
| Q4 2016 | $239,806,450,000 | -5.5% | 2,332,067 | +0.6% | 1.96% | -10.4% |
| Q3 2016 | $253,733,728,000 | -1.9% | 2,317,203 | +1.0% | 2.19% | -3.5% |
| Q2 2016 | $258,602,021,000 | +14.9% | 2,293,181 | -3.7% | 2.27% | +20.3% |
| Q1 2016 | $225,162,897,000 | +55.5% | 2,382,172 | +48.1% | 1.89% | +36.3% |
| Q4 2015 | $144,779,850,000 | +133.8% | 1,608,665 | +140.1% | 1.38% | +134.7% |
| Q3 2015 | $61,937,197,000 | +10.5% | 669,881 | +17.7% | 0.59% | +15.5% |
| Q2 2015 | $56,036,224,000 | -5.5% | 569,069 | -3.8% | 0.51% | -5.2% |
| Q1 2015 | $59,318,927,000 | +9.3% | 591,474 | +0.7% | 0.54% | +6.1% |
| Q4 2014 | $54,253,954,000 | – | 587,164 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |